H.R. 6710 · 117th Congress
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to…
Full title
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
HerrellSponsor20 cosponsors · 20 R
R
Banks
KC
R
Cammack
MC
R
Cawthorn
BD
R
Donalds
LG
R
Gohmert
RH
R
Hudson
CH
R
Higgins
KH
R
Hern
FK
R
Keller
JL
R
LaTurner
DM
R
McKinley
MM
R
Miller
MM
R
Miller-Meeks
RN
R
Norman
AS
R
Scott
TM
R
Mann
BB
R
Babin
VH
R
Hartzler
RJ
R
Jackson
AM
R
Mooney15 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.
What it does: CRS summary · Introduced in House · Feb 11, 2022
This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.
The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.
Latest action (Feb 14, 2022): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Feb 11, 2022
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.